Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: J Glaucoma. 2009;18(5):341–353. doi: 10.1097/IJG.0b013e31818c6ef6

Friend or Foe? Resolving the Impact of Glial Responses in Glaucoma

Elaine C Johnson 1, John C Morrison 1
PMCID: PMC2697444  NIHMSID: NIHMS85786  PMID: 19525723

Abstract

Glaucomatous vision loss results from the progressive degeneration of optic nerve axons and the death of retinal ganglion cells. This process is accompanied by dramatic alterations in the functional properties and distribution of glial cells in both the retina and the optic nerve head in a reaction commonly referred to as glial activation. The recent availability of rodent and cell culture glaucoma models has substantially contributed to our knowledge of glial activation under glaucomatous conditions. Conclusions drawn from these studies have led to the refinement of existing hypotheses and the generation of new ones. Because these hypotheses encompass both protective and injurious roles for glia, the impact of specific aspects of glial activation are current topics of intensive research, speculation and debate in the field. With these unresolved issues in mind, this review will summarize recent progress in our understanding of the process of glial activation in the glaucomatous optic nerve head and retina.

Keywords: astrocytes, microglia, optic nerve head, retina, glaucoma, intraocular pressure, gliosis

Introduction

The optic neuropathy of glaucoma is characterized by a predictable pattern of visual field loss and optic disk cupping. Cupping reflects a loss of axons in the prelaminar optic nerve head (ONH) and a backward bowing of the lamina cribrosa accompanied by extensive remodeling of the associated extracellular matrix (ECM). In the retina, there is selective loss of retinal ganglion cells (RGC) and nerve fiber layer thinning. Elevated intraocular pressure (IOP) is the most recognized glaucoma risk factor and controlling IOP is the foundation of current glaucoma therapy. In addition, aging, diabetes, race, hypertension, myopia, steroid exposure and family history all contribute to the risk of developing this disease.1

Historically, it has been generally hypothesized that elevated IOP results in ischemic or mechanical injury to optic nerve axons at the level of the ONH leading to axon degeneration and RGC death. Currently, the specific cellular mechanisms by which elevated IOP, or any other risk factor, results in glaucomatous optic nerve degeneration and RGC loss are not fully understood. However, recent investigations suggest that glial cells may play strategic roles in this injury process.

In glaucomatous neuropathology, glial cells of the retina and ONH are known to change their morphology and their protein expression in a process referred to as glial activation. The specifics of activation differ, depending on the cell type and localization. In the retina injured by experimental IOP elevation, glial fibrillary acidic protein (GFAP) appears upregulated in astrocytes and Müller cells. In corresponding ONH, the normal columnar organization of glial nuclei is disrupted and there is increased expression of ECM proteins. Eventually, axonal debris is phagocytosed, the neural area contracts and is replaced by a GFAP-positive astrocytic scar.2 Under normal conditions, astrocytes and Müller cells are believed to maintain the homeostasis of extracellular ions, glucose and other metabolites, water, pH and neurotransmitters such as glutamate and gamma-aminobutyric acid. They are also thought to contribute to the blood-brain barrier.3 In uninjured neural tissues, microglia, the immune cells of the brain, actively survey their microenvironment via extremely motile processes and protrusions.4 Following injury, microglia hypertrophy, remove debris from the injured area and may proliferate, secrete cytokines and act as antigen presenting cells. In contrast to traumatic injuries that disrupt the blood-brain barrier, in glaucoma there is at present no evidence for invasion of inflammatory cells.5

In the glaucomatous activation of glia cells, it is critical to determine the impact of specific aspects of these processes. Hypothetically, some changes could be enhancements of the normal, supportive functions of glial cells that may protect axons and RGC from further injury, as illustrated classically by ischemic preconditioning.6 Alternatively, glial activation may result in the triggering of processes that result in further injury, as illustrated by glutamate excitotoxicity with reperfusion following ischemia in brain.7, 8 These dichotomous glial responses are undoubtedly accompanied by many epiphenomena that have no impact on neuronal or axonal survival and are merely secondary responses to axonal degeneration and a challenge to glial homeostasis.

While the alteration in glial cell function associated with glaucoma has drawn the attention of researchers for many years, at least 50% of all original research articles and 75% of all reviews on this topic have been published since 2000. In 2008, the ARVO Pfizer Research Institute sponsored a meeting focused on the role of glia in glaucoma and a report from that meeting should be in press soon (http://www.arvo.org/EWEB/DynamicPage.aspx?site=foundation&WebCode=4thannualconf). One reason for research progress in recent years is undoubtedly the development of rodent and cell culture models to examine various aspects of glial response in injury induced by elevated IOP exposure or other hypothesized injury factors.9-13 This review summarizes recent progress in understanding the roles of astrocytes, Müller cells and microglia in the two neural regions most affected by glaucoma, the optic nerve head and ganglion cell layer of the retina. While undoubtedly closely interrelated, axonal degeneration and RGC loss appear to be separately regulated biological processes.14 Therefore, progress in our understanding of glaucomatous glial reactions in the ONH and retina will be discussed separately. These discussions will be followed by a brief consideration of the impact of the important risk factor of age on glial reactions in glaucoma. Finally, in the conclusion, we will consider the implications of new developments and highlight areas warranting further investigation.

ONH ASTROCYTES AND RESPONSES TO GLAUCOMATOUS INJURY

Astrocytes are the most prevalent glial cell in the ONH and astrocyte studies in human and experimental glaucoma dominate the recent ONH literature. In the normal anterior portion of the ONH, astrocyte cell nuclei are arranged in columns separating the axon bundles, with their GFAP-labeled processes oriented perpendicular to the nerve fibers. In the lamina and at vascular and pial surfaces within the nerve head, astrocytes and their processes are interposed between these tissue components and axons. Reactive astrocytes are generally characterized by hypertrophy, hyperplasia, as well as increased expression of GFAP and vimentin.15 In glaucoma or with experimentally elevated IOP, ONH astrocytes in the prelaminar ONH round up and migrate, abandoning their columnar organization. In experimental glaucoma, GFAP immunolabeling intensity and mRNA expression vary during the course of the injury process and scar formation, suggesting variations in the organization and abundance of the cytoskeletal protein.2, 16-18

Astrocyte-Mediated Alterations in the ONH Extracellular Matrix (ECM)

Changes in ONH ECM composition and organization in glaucoma are well recognized, including the deposition of ECM materials in areas formerly occupied by axons. These changes are likely to contribute to the altered biomechanical properties of the glaucomatous ONH that may increase the vulnerability of remaining axons.19, 20 Astrocytes are thought to play the major role in the process of ECM remodeling.5 Fibrillar collagens I and III, basement membrane collagen IV, microfibrillar collagen VI, tenascin C and elastic ECM components increase and appear disorganized.21-24 New evidence suggests that genetic differences in elastin exon splicing, synthesis rates and maturational crosslinking may contribute to the higher risk of glaucoma in individuals of African ancestry.25 To model glaucoma, ONH astrocytes have been exposed to hydrostatic pressure or mechanical stretch in vitro, resulting in the upregulation of many of these same ECM components.12, 13, 24, 26 Glaucoma modeling in the rat in our laboratory suggests that specific ONH ECM protein messages, such as fibulin 2 and tenascin c, are most increased early in the injury process while other ECM components, such as periostin, collagen VI and IV, show increases that parallel the extent of nerve degeneration. These data lead to the concept that ECM changes in glaucoma are not static. Instead, progressive and variable alterations in the composition of the ECM accompany and may play a direct role in the response to pressure-induced ONH injury as well as the recovery from axon loss.18

Increased tissue stress in the ONH from elevated IOP may be detected by glial cells via transmembrane integrin receptor signaling. Integrins α2, α3, α6, β1, and β4 are localized within the glial columns and laminar beams of the human ONH, providing receptors for fibrillar and basement membrane collagens, fibronectin, laminin, tenascin, periostin, complement 1q, matrix metalloproteinases, reelin, and astroctyic hemidesmosomes.27-33 In human glaucoma, reduced α6 integrin in the prelamina may reflect astrocyte migration and reorganization, while increased α4 labeling suggests microglial activation.28, 34

While integrins act as mechanoreceptors, transducing the stresses induced by elevated IOP, the matrix metalloproteinases (MMP) are key elements in the regulation of ECM remodeling.35 Several MMP and their inhibitors, the tissue inhibitors of MMP (TIMPs), are present in ONH astrocytes. MMP1, 2 and 3, as well as membrane type1-MMP appear to be increased in glaucomatous human and in monkey ONH following exposure to elevated IOP.36-38 These responses may be specific to pressure-induced injury, as similar increases are not observed in the ONH following optic nerve transection.36 In rat ONH following extensive axon degeneration, mRNA for several MMP are increased, while levels of TIMP1 showed the greatest increase in ONH with focal injury.18 MMP-related remodeling of the ECM is likely to be a major contributor to the changes in the biomechanical properties of the glaucomatous ONH, but alterations in MMP levels may also contribute to an improved potential for axonal regeneration. Increased expression of MMP, coupled with decreased TIMP, have been linked to a more permissive environment for optic nerve axon outgrowth following crush injury.39

Altered Gap Junctional Communication

While integrins and other receptors allow astrocytes to sense extracellular changes, astrocytes are also metabolically and ionically linked by gap junctions, forming a syncytium. In our rat glaucoma model, we found a loss of immunohistochemical connexin-43 gap junctional labeling at three days following IOP elevation.2 Similarly, ONH astrocytes exposed to hydrostatic pressure demonstrate decreased gap junctional coupling, apparently mediated by epidermal growth factor receptor and associated with an increase of intracellular and nuclear connexin-43 phosphorylation.40 Loss of gap junctional communication may have mixed effects on glaucomatous injury since reduced communication restricts the spread of injurious ions or metabolites, but simultaneously intensifies local damage by reducing the buffering effect of their distribution. Inhibition of astrocytic gap junctional coupling is has also been associated with increased astrocyte proliferation and is supported by increased glucose utilization via the pentose-phosphate pathway to produce ribose for nucleic acid synthesis.41

Astrocyte Proliferation And Migration

When normal human ONH astrocyte cultures were exposed to hydrostatic pressure, Hernandez found a two-fold increase in the number of cells after one day and an approximately five-fold increase after three to five days.12 At three days following IOP elevation in our rat glaucoma model, the labeling of anterior ONH glial nuclei with antibodies to proliferating cell nuclear antigen coincided with the first alterations in connexin-43 labeling and preceded obvious morphological alterations in the glial columns.2 More recently, we used the same rat model and microarray analysis to compare gene expression in ONH with extensive axonal injury to that in the normal ONH. In this study, the most significantly regulated biological process was cell proliferation, an observation confirmed by an almost three-fold increase in ONH DNA content.18 Also significantly affected were cell migration and adhesion processes. Pressure-induced cell proliferation was also indicated by a near doubling of optic nerve astrocytes in a mouse glaucoma model.42 When astrocytes cultured from normal and glaucomatous human ONH were compared in functional studies, the glaucomatous astrocytes were less adhesive and migrated more rapidly, as reflected by gene expression profiling in the same study.43 Considered together, these studies suggest that elevated pressure exposure results in ONH astrocyte proliferation, as well as altered adhesion and migration properties. Recently, ONH astrocyte migration in vitro has been shown to be regulated via multiple kinase signal transduction pathways.44, 45

Re-expression of Developmental Proteins

Astrocytes from glaucomatous ONH may upregulate or re-express proteins normally associated with neural and glial differentiation during development.5 Vimentin, characteristically found in immature astrocytes, appears increased in experimental glaucoma ONH in monkeys,46 as well as in ONH astrocytes exposed to hydrostatic pressure.47 Nestin, another developmental intermediate filament protein, is also upregulated in glaucomatous rat ONH.18 The embryologically expressed, bidirectional signaling molecules Ephrin B1 and Eph1B are upregulated in experimental primate glaucoma ONH and in ONH astrocytes cultured from glaucomatous human ONH,48 while in a genetic mouse glaucoma model, the upregulation of ephrin B2 and EphB2 in glia is associated with elevated axonal calcium and axon loss.49 Ephrin signaling is involved in maintenance of shape, movement and attachment. Following neural injury, ephrins and Eph are generally upregulated and appear to have differential effects on axons and glia. Ephrins inhibit axon regeneration and induce growth cone collapse, while they stimulate glial activiation.50

Neurotrophins (NT) And Cytokines In Astrocytic Responses

NT and NT Receptors

Cultured human optic nerve astrocytes express and secrete NT of the nerve growth factor family and their associated Trk receptors.51 Exposure of these cells to exogenous NT leads to receptor phosphorylation, astrocyte proliferation and an altered composition of secreted NT.52 In addition, exposure of cultured ONH astrocytes to ischemic conditions resulted in altered NT and NT receptor expression.53 In immunohistochemical studies of ONH responses in a rat glaucoma model, immunolabeling for brain-derived neurotrophic factor (BDNF) and NT4/5 in the ONH appeared increased by extensive injury, suggesting in vivo NT upregulation by ONH astrocytes.2 These observations together suggest that altered autocrine or paracrine astrocytic NT responses may be evoked during ONH glaucoma pathogenesis.

Transforming Growth Factor Beta (TGFβ) and the TGFβ Superfamily

TGFβ contributes to glial proliferation, differentiation and the regulation of ECM composition.54, 55 Although ONH immunolabeling for both TGFβ1 and TGFβ2 appeared increased in monkeys with experimental glaucoma,,56 further studies using human glaucomatous ONH explants and bioassays have implicated astrocytic TGFβ2 as a key modulator of glaucomatous responses.57 In addition, TGFβ2 stimulates cultured ONH astrocytes to increase production of basement membrane and other ECM components.58 The role of TGFβ2 in the pathogenesis of glaucoma has been reviewed.59 In our recent studies of ONH gene expression using our rat glaucoma model, we found evidence for differential regulation of TGFβ1 and TGFβ2 mRNA levels. The level of TGFβ1 increased linearly with increasing pressure-induced nerve injury, while that of TGFβ2 did not.18

In addition to TGFβ, other members of the TGFβ superfamily have been hypothesized to play roles in glaucomatous ONH injury. Microarray studies indicate an upregulation of betaglycan (TGFβ receptor III) in isolated glaucomatous ONH astrocytes.43 In a rat glaucoma model ONH, mRNA for TGFβ receptor 1 and 2, plus a number of TGFβ pathway regulators were altered in expression.18 Isolated human ONH astrocytes express mRNA and protein for TGFβ family members, including bone morphogenic proteins (BMP) 2, 4, 5 and 7, glial derived neurotrophic factor, their receptors and a number of BMP inhibitory and signaling proteins.60, 61 BMP signaling pathway mediators are induced in ONH astrocytes by exogenous BMP4 application.62 BMPs promote proliferation of glial precursors and astrocytic differentiation.63 Together, these observations suggest that members of the TGFβ superfamily play diverse roles in the glaucomatous ONH responses that remain to be elucidated in greater detail.

Tumor Necrosis Factor Alpha (TNFα)

TNFα and TNFα receptor 1 are expressed in the glaucomatous human ONH38, 64 Cultured ONH astrocytes express TNFα receptor and, in response to exogenous TNFα, produce inducible nitric oxide synthase and endothelin-1 (ET-1), two proteins proposed to play key roles in glaucomatous ONH responses.64, 65

Endothelin Dysregulation

Numerous reports of elevated concentrations of ET-1 in the aqueous humor and plasma of individuals with glaucoma support a role for the dysregulation of this potent vasoconstrictor in the pathogenesis of glaucoma.66-70 Mechanical stress, ischemia and cytokines, such as TNFα and TGFβ, all induce the expression and secretion of ET-1 in ONH cells.65, 71, 72 Administration of exogenous ET-1 to the ONH of monkeys or rats produces an optic neuropathy ascribed to ischemia that has demonstrated some clinical similarities to the optic neuropathy of glaucoma,73, 74 including optic cup enlargement,75 and regional axon loss.76, 77

Separately from its ability to induce ischemia, ET-1 is also an important glial mitogen.78 Exposure of cultured ONH astrocytes to ET-1 results in a 30% increase in cells in a 96 hour period.79 This proliferation appears mediated via several parallel signaling pathways.80 In addition to the vascular and proliferative effects of ET-1, it also increases the expression of MMPs and their inhibitors, thus contributing to ECM remodeling.81

In rat eyes with elevated IOP, ET-1 levels in the aqueous humor increased and immunolabeling for ET-1 and ET receptor B appeared increased and co-localized with GFAP in the ONH.82 ET receptor B mediates the vasodilative actions of ET-1 (in contrast to its vasoconstrictive functions mentioned above) and is associated with endosomal uptake and lysosomal degradation of extracellular ET-1, while ET receptor A mediates the vasoconstrictive effects of the signaling protein.83 Recent studies of human glaucomatous and experimental monkey ONH have confirmed an increase in astrocytic ET receptor B immunostaining.84 In general, levels of this receptor are down-regulated during astrocyte proliferation,85 and, in fact, message levels for ET receptor B were found to be downregulated coincidental with evidence of ONH cell proliferation in our recent rat glaucoma microarray analysis.18 Therefore, evidence from human and experimental glaucoma supports a role for increased ET-associated vasodilative responses as well as astrocytic proliferation.

Evidence of Oxidative Stress

Oxygen-dependent metabolism inevitably produces reactive oxygen species, such as superoxide, peroxide and hydroxyl radicals. These are normally detoxified by endogenous antioxidant processes. During periods of hypoxia, metabolic or other cellular stress, reactive oxygen species may accumulate to a point that critical cellular functions are damaged. In various neurodegenerative diseases, localization of tissue markers of oxidative stress to lesion areas has led to suggestions that oxidative injury contributes to the disease process. Exposure to oxidant insult may also upregulate antioxidant levels to enhance endogenous neuroprotection. For example, exposure to a lipid peroxidation product, 4-hydroxynonenal, increases levels of ONH astrocytic glutathione and antioxidant enzymes.86 Therefore, oxidative stress may play a role as a primary injurious event, contribute to the propagation of injury, or provide a stimulus to increase endogenous neuroprotective mechanisms or more downstream by-products of the injury process. The relative importance of each of these roles in neurodegeneration remains unclear.87

Oxidative stress can promote the production of advanced glycosylation end-products (AGEs) that are commonly associated with aging and diabetes, and AGEs exacerbate oxidative stress.88-90 Recently, increased immunolabeling for AGEs and the AGE receptor, RAGE, have been found in the ONH of glaucomatous human eyes.91 While labeling for AGEs was primarily associated with the lamina cribrosa, RAGE was co-localized with GFAP, suggesting that astrocytic responses to extracellular AGEs may play a role in glaucomatous glial activation and migration.

Nitric Oxide Dysregulation

The isoforms of nitric oxide synthase (NOS), neuronal, inducible (iNOS) and endothelial, play important roles in neural transmission, defense responses and vascular dilation, respectively. It has been hypothesized that, in reperfusion injury following ischemia, excessive nitric oxide production by NOS may react with superoxide to produce the damaging free radical peroxynitrite. While human glaucomatous and rat glaucoma model ONH showed positive immunolabeling for all three isoforms, the apparent increase of iNOS in ONH glial cells in glaucomatous human ONH led to the hypothesis that overproduction of iNOS leads to axon loss.92-95 In support of this hypothesis, cultured astrocytes were shown to increase iNOS mRNA and protein in response to exposure to hydrostatic pressure,96 and two iNOS inhibitors were found to be neuroprotective in experimental studies using a rat glaucoma model.97, 98 In the same rat glaucoma model, IOP control with timolol was found to decrease both iNOS and nNOS ONH immunolabeling.99 However, other studies of human glaucoma and experimental rodent glaucoma models found no evidence of iNOS upregulation, nor was pharmacologic iNOS inhibition found to be neuroprotective.100-102 Therefore, the role iNOS in the pathogenesis of glaucomatous ONH injury remains controversial.

Epidermal Growth Factor Receptor (EGFR) Activation

EGFR is widely involved in the regulation of growth and differentiation of cells, including neuroglia. The linking of EGFR activation to the induction of iNOS in cultured human astrocytes led to observations that EGFR is upregulated and phosphorylated in human glaucomatous ONH. Further in vitro studies demonstrated that exposure of human ONH astrocytes to increased hydrostatic pressure resulted in receptor phosphorylation and nuclear translocation, suggesting that EGFR activation plays a role in glaucoma pathogenesis.103 Activation of EGFR led to the induction of cyclooxygenase-2 and prostaglandin e2 in ONH astrocytes,104, 105 affected the three-dimensional organization of astrocytes and their interaction with neurites,106 and appeared associated with the process of astrocyte activation and migration.45, 107 These observations led to the hypothesis that the activation of ONH astrocytic EGFR plays an injurious role in glaucoma.108 However, EGFR activation in astrocytes can also promote cell survival, glutamate transport and functional support of neurons, suggesting the need for a more complete understanding of the potentially varied roles of this receptor in the ONH.109, 110

Dysregulation of Steroid Metabolism

Corticosteroid exposure is a well known risk factor for glaucoma through its potential effects on aqueous humor outflow via the trabecular meshwork.111 However, the effects of steroids on ONH glial cells are only beginning to be explored. When cultured porcine ONH astrocytes were exposed to dexamethasone, the expression levels of two genes implicated in glaucoma pathogenesis, optineurin and myocillin, were altered, suggesting that corticosteroid exposure may have in vivo effects on ONH astrocyte function.112

Elevated levels of 3-hydroxysteroid dehydrogenases (HSD) are found in astrocytes from glaucomatous human and experimental monkey ONH. These enzymes are induced by oxidative stress and metabolize many endogenous steroid isoforms. 3α-HSD immunostaining appears intensified in reactive astrocytes in human and experimental monkey glaucomatous ONH and, when normal astrocytes are exposed to hydrostatic pressure, 3α-HSD mRNA is increased113 In the same study, an enhanced conversion of androgen 5α-dihydrotestosterone to neuroactive 5 α-androstane-3 α,17β-diol (3α-diol) by astrocytes from glaucomatous eyes was observed. Cultured ONH astrocytes exposed to 3α-diol demonstrate increased levels of androgen receptor (AR) protein and evidence of the activation of kinase signaling pathways, demonstrating that astrocytes are potential targets of neuroactive androgens.114 In ONH from monkeys with experimental glaucoma, demonstration of increased astrocytic immunostaining for AR and for nuclear factor kappa b, a transcription factor implicated in the upregulation of AR, led to the suggestion that altered androgen metabolism may play a significant, potentially neuroprotective, role in glaucoma pathogenesis.115

Astrocytic Immune Responses

Glaucomatous ONH, as well as cultured ONH astrocytes subjected to ischemic conditions, interleukin 10 or interferon gamma, demonstrate increased levels of major histocompatibility complex antigens. Immune responses may also be enhanced by oxidative stress. When ONH astrocytes were treated with reactive oxygen species, they expressed major histocompatibility complex class II proteins and became more potent inducers of T-cell activation.116 This suggests that ONH astrocytes can function as antigen presenting cells and may evoke immune responses that contribute to the initiation and progression of glaucomatous injury.117

Roles for ONH Microglia In Glaucoma

ONH microglia are much less numerous than astrocytes and their responses in glaucomatous ONH injury have not been extensively studied. Given their important roles in phagocytosis, surveillance and immune responses,4, 118-120 a better understanding of their functions in the normal and glaucomatous ONH is warranted. For instance, it is intriguing that nitric oxide production by isolated microglia is at least an order of magnitude greater than that for astrocytes.121 Microglia are distributed throughout the ONH, particularly in association with the elements of the vasculature. In glaucoma, they hypertrophy, reorganize, and increase in density near the peripapillary choroid.17, 122 These activated microglia demonstrate increased immunolabeling for TNFα, TNF receptor-1, TGFβ2, proliferating cell nuclear antigen, cyclooxygenase 2, MMP and TIMP proteins.64, 95 In our rat glaucoma model, the expression level of a microglial marker, ionized calcium binding adapter molecule 1, was positively correlated with the extent of axonal degeneration.18 TNFα-associated microglial activation has been proposed to lead to loss of optic nerve oligodendroglia in a mouse glaucoma model.123 In addition, the increased immunolabeling for integrin α4 that we observed in human glaucomatous ONH and the upregulation of many microglial associated messages in glaucomatous rat ONH may also reflect microglial activation.18, 28 Reactive microglia are also implicated as sources of reactive oxygen species, as well as initiators of both protective and destructive immune responses.124

GLAUCOMATOUS RESPONSES IN RETINAL GLIA

Three glial cell types are recognized in the inner retina: astrocytes, Müller cells (together termed macroglia), and microglia. Located within the nerve fiber layer, astrocytes can appear either elongated, with processes oriented parallel to the nerve fiber bundles and without apparent vascular contact, or stellate, having an oval appearance with processes crossing nerve fiber bundles and contacting the vasculature. Stellate astrocytes are primarily located at the level of RGC soma.125, 126 Müller cells, whose nuclei lie within the inner nuclear layer, have vertically oriented processes that span the entire thickness of the retina, their inner foot processes forming the internal limiting membrane. Ultrastructural studies indicate that interactions among these glia exist, since desmosomes are present between astrocytes and Müller cells, although gap junctions exist only between astrocytic foot processes.126 Also, both appear to contribute to the internal limiting membrane, the vascular glia and glial sheaths of the retinal ganglion cells. Microglia appear ovoid or amoeboid in the normal retina, usually within the ganglion cell and inner plexiform layers.

Macroglia appear to supply metabolic support for RGC cell bodies and axons, modulate the extracellular ionic balance, regulate local concentrations of neurotoxic compounds and produce neurotrophic factors. 126, 127 127-129 They are thought to function as intraretinal phagocytic cells during development, in various retinal diseases and following optic nerve transection.130

Retinal Glial Cell Activation in Glaucoma

Glial activation in the glaucomatous retina has been suggested to have both injurious and protective effects on RGC.130-132 Evaluations of retinal sections from glaucomatous eyes have demonstrated an increase in label for the catalytic forms of mitogen activated protein kinases in glial cells, leading to the suggestion that these signaling pathways may be responsible for glial activation. Further, activation of these pathways is also associated with cell survival and glial cells are relatively protected in the glaucomatous retina as compared to RGC, which lack similar kinase activation.133 However, processes that enhance glial survival in injured retinas could simultaneously sustain their supportive functions. This alternative was suggested by the observation that exposure to elevated IOP increases Müller cell expression of the anti-apoptotic protein, BCL-2, which may enhance Müller cell survival and effective function, thus indirectly protecting RGC.134 Another example of the potential of glial cells to offer protection to RGC is the demonstration that Müller cells can be a source of neurotrophic support.135 This possibility is discussed further below.

Experimental elevation of IOP also results in retinal microglial activation, identified by an increase in the size and number of microglial cells throughout the retina.130, 136 Proliferation of microglia in the inner retina has also been demonstrated in a genetic mouse glaucoma model.137 These responses, as well as those of macroglia, were temporally and spatially correlated with downregulation of neuronal markers, suggesting that glial responses are closely associated with glaucomatous neuronal degeneration. However, whether glial responses play a pivotal role in RGC death, or simply represent a secondary reaction to neuronal damage, such as the removal of cellular debris, is currently unknown.

Intermediate Filament Protein Expression in Activated Retinal Macroglia

The intermediate filament protein, GFAP, is exclusively expressed in macroglia and is generally used as a marker for astrocytes. In normal eyes, retinal astrocytes label with antibodies to GFAP, while Müller cells demonstrate little labeling.130, 138 Increased GFAP expression occurs in a wide variety of retinal pathologies including ischemia and macular degeneration and is commonly used to identify glial activation. Multiple investigations using various experimental and genetic glaucoma models indicate that GFAP expression is increased, probably in both retinal Müller cells and astrocytes,17, 130, 132-134, 137-142 143 although there is some evidence of decreased expression in retinal astrocytes.144 A study of GFAP-labeled astrocytes in human glaucomatous retinas found evidence of increased cell density in the peripapillary region and in association with the vasculature, while nerve fiber layer astrocytes did not appear altered.145 In a murine glaucoma model, the upregulation of GFAP in macroglia following exposure to elevated IOP appeared to occur without evidence of proliferation.137

There are conflicting reports as to whether expression of vimentin, another intermediate filament protein present in retinal glia, is altered by elevated IOP.17, 138, 143 Nestin, a third intermediate filament, considered by some a marker of neural progenitor cells, has been identified in Müller cells and some astrocytes of the ganglion cell layer. Increased expression of nestin in experimental rat glaucoma may represent an early, neuroprotective response to neural injury.142

Heat shock proteins (HSP) Upregulation

HSP function as cellular chaperones by assisting in protein folding. They have been found to increase in expression following injury and are thought to enhance neuronal survival. HSP immunolabeling was increased in glaucomatous human retinas, where it was primarily localized to RGC, although there was some increase in labeling of glial portions of the internal limiting membrane.146 Increased retinal HSP expression has been found in several models of chronically elevated IOP as well.138, 143, 147, 148 In a rat experimental glaucoma model, pharmacologic HSP induction offered neuroprotection.149 In another study, elevated IOP exposure increased immunoreactivity to HSP in the nerve fiber layer, and colocalized with cells labeled by GFAP and vimentin, suggesting that glial cell HSP may play a neuroprotective role.143

Altered Iron Regulation

Studies in several animal models with elevated IOP and in human glaucoma eyes suggest a potential role in glaucoma for proteins involved in iron regulation. All of these studies have found upregulation of ceruloplasmin message in the retina,138, 139, 150, 151 with some detecting commensurate elevation in protein levels.150, 151 Significantly, immunohistochemistry localized this increase to the Müller cells and inner limiting membrane, which is composed primarily of Müller cell end feet.151 Ceruloplasmin, a glycoprotein whose role in copper transport in the blood is well known, is synthesized in CNS glial cells, and by retinal macroglia.152 Here it is believed to play a role in converting ferrous iron, which is toxic, to ferric iron, which binds to transferrin, a protein responsible for intracellular delivery of iron. Interestingly, retinal expression of transferrin, as well as ferritin, a major, non-toxic storage form of iron, has also been found to increase following experimental elevation of IOP in monkeys and in human glaucoma eyes.150 Since all three proteins are involved in iron regulation, and may function as antioxidants, it has been proposed that upregulation of these proteins is an endogenous protective retinal response, mediated most likely by glial cells, to excess iron or oxidative stress.150, 151 Whether this response is a direct effect of elevated IOP or a response to RGC injury is unknown, and the possibility that these responses might actually contribute to the primary mechanisms of RGC loss has not been totally ruled out. Resolving these possibilities could be critical to eventually developing strategies that manipulate these or other iron-regulating genes to produce effective neuroprotective treatments for glaucoma

NT and NT Receptor Responses in Macroglia

The survival of RGC may depend upon the availability of NT, and it has been proposed that RGC death in glaucoma results from loss of neurotrophic support due to the obstruction of retrograde transport of brain-derived neurotrophic factor (BDNF) and its TrkB receptor at the ONH.153 Gene transfer to increase RGC BDNF expression or activate TrkB-mediated survival signaling pathways has been shown to enhance both somal and axon survival in rat glaucoma models.154, 155 Interestingly, adenoviral transfection of Müller cells with a transgene expressing BDNF delayed RGC death following optic nerve transection.135 A similar experiment in a glaucoma model has not yet been performed, but a comparable response would suggest another potentially exciting, neuroprotective role for glial cells in this condition.

Both BDNF and TrkB can be synthesized locally within the retina, and could affect RGC survival in either autocrine or paracrine fashion.156-158 In a model of experimental IOP elevation, retinal levels of NT and receptor mRNA were altered, including the upregulation of TrkC receptor, apparently localized to the Müller cells, and a late increase in p75, a pro-apoptotic receptor that also has the ability to enhance cell survival pathways under specific circumstances.159 In addition, exposure to glutamate has been shown to increase expression for several NT in cultured Müller cells.160 These observations suggest that the reactive response of retinal glial cells in glaucoma may include events that directly affect the survival or loss of RGC.

The Potential of Glutamate Excitotoxicity

Initial reports of elevated levels of glutamate, a major central nervous system excitatory neurotransmitter, in the vitreous of glaucomatous human eyes161 and in glaucoma models161 introduced the possibility that RGC death in glaucoma could be mediated by excitotoxicity from prolonged stimulation of glutamate receptors, including NMDA receptors, and elevated intracellular calcium. It was hypothesized that elevation of glutamate resulted from a reduction in glutamate transporters, normally responsible for internalization of glutamate, and the reduced activity of glutamate synthetase, which is responsible for metabolizing glutamate. Glutamate transporters and glutamine synthetase have been located in retinal astrocytes and Müller cells,162 suggesting an important role for glial cells in this process.163 In fact, glutamine, a precursor in the formation of glutamate, and glutathione, a metabolite of glutamate, have both been found increased in Müller cells in monkeys with elevated IOP.164, 165 A recent study of mice deficient in glutamate transporters has demonstrated reduced levels of glutathione in Müller cells coupled with spontaneous RGC and optic nerve degeneration without elevated IOP. RGC loss in these mutants was prevented by administration of glutamate receptor blockers.166 However, in rat glaucoma models, there are conflicting reports regarding alterations in retinal glutamine synthetase and glutamate transporter levels.134, 167, 168

The possibility that excess glutamate contributes to RGC death in glaucoma is controversial. Studies in monkeys169, 170 and rats171 with experimental glaucoma, as well as human glaucoma eyes,172 have failed to confirm initial reports of elevated vitreous glutamate levels. Recent work using imaging of retinal ganglion cell calcium failed to show functional evidence of altered glutamate clearance in retinas from rats with chronically elevated intraocular pressure and optic nerve and retinal damage .173 In other studies, glutamate was found to stimulate upregulation of NT expression in Müller cells, potentially augmenting the supply of NT.160 Finally, cell culture and in vivo analyses have demonstrated that the RGC is relatively invulnerable to high concentrations of glutamate and NMDA, despite substantial injury to amacrine cells.174 While the glutamate hypothesis presents an intriguing view of how altered function of retinal glial cells might contribute to RGC death, the initial release of findings of multicenter clinical trial of memantine, an NMDA inhibitor, in patients with chronic glaucoma reported no significant benefit of drug treatment compared to placebo. (http://agn360.client.shareholder.com/releasedetail.cfm?ReleaseID=290764)

Evidence of immune System Dysfunction

The observation that glaucomatous visual loss can proceed in the apparent absence of elevated IOP suggests that a number of other factors may influence this process. Among others, the potential that the immune system may contribute to glaucomatous nerve damage through an autoimmune mechanism has been suggested and thoroughly reviewed by Tezel and coworkers.131, 175, 176 Both normal tension and open angle glaucoma patients have been found to have increased serum autoantibodies to small HSP.177-179 In addition, the direct application of antibodies to small HSP appears to induce apoptosis in cultured retinal ganglion cells.179 These observations, coupled with the evidence that glial cells have the capacity to be antigen-presenting cells, suggests that retinal glia may contribute to immune responses that ultimately are destructive to RGC.146 116, 175

Involvement of the immune system in glaucomatous processes is suggested by the dramatic upregulation of components of the complement cascade in monkey and rat retinas following experimental IOP elevation and a mouse genetic glaucoma model with a demonstrated immune component.132, 138, 139, 180 Complement expression may play a role in the process of glial activation. Increased expression and immunolocalization of complement cascade components and the membrane attack complex were found in RGC soma and along the vitreal surface in both human glaucoma and a rat model of elevated IOP, but did not co-localize with GFAP.141 The upregulation of complement cascade components has been confirmed in a genetic mouse glaucoma model in which immunolabeling of immature glial or Müller cells with complement antibodies was associated with elimination of inner plexiform layer synapses.181, 182 This linkage offers an explanation for the shrinkage and remodeling of the dendritic tree in specific RGC subtypes that has been demonstrated in experimental primate glaucoma183 and suggests a role for glial cells in this degenerative process.

TNFα, The TNF Receptor Superfamily and RGC Apoptosis

Specific increases in the number of cells labeling for TNFα and its receptor have been described in the inner retina of glaucomatous human eyes compared to normals.184 These increases were apparently localized to glial cells and RGC, respectively, suggesting that this aspect of glial cell reaction in glaucoma may also contribute to RGC death. When isolated retinal glial cells were exposed to increased hydrostatic pressure, they secreted TNFα and induced apoptosis in co-cultured RGC.185 Increased levels of immunoreactivity for Fas and FasL, a member of the TNF receptor superfamily, werefound to correlate with increases in labeling for both microglia and astrocytes.140 While activation of the Fas/FasL receptor can be protective under certain circumstances, it often results in apoptosis via caspases. The exclusive co-localization of caspases with GFAP in the retina in a rodent glaucoma model led to the suggestion that glial cells are actively involved in the initiation of RGC apoptosis.186 More recent evidence of increased Müller cell reactivity for Fas-associated death domain (FADD), an important component for Fas-caspase-mediated apoptosis, further strengthens the possibility that glial cells contribute to RGC apoptosis from elevated IOP.140

Retinal Microglial Responses

As is the case in the ONH, the specific roles of retinal microglia in glaucomatous injury have not been as extensively studied as those of other retinal glia. There are numerous reports of microglial proliferation and hypertrophy in retinas in experimentally induced glaucoma.130, 131, 136, 137, 140 They, too, express Fas/FasLimmunoreactivity, which increases in experimental glaucoma.140 In a genetic mouse glaucoma model, microglia were the only glial cells to proliferate in the retina during the course of the disease.137 In this same model, suppression of microglial activation with minocycline appeared to be protective of RGC integrity.187 Clearly, much more work remains to be done to understand better how retinal microglia influence RGC death in glaucoma.

AGING AND GLIAL RESPONSES IN GLAUCOMA

Aging is an important risk factor for glaucoma and also a consideration when modeling glaucoma in animals. We routinely use mature adult (8 month old) rats, but the use of very elderly animals does impact experimental responses. For example, in comparison to adult rats, we find that the optic nerve of aged (28 month old rats) is significantly more susceptible to injury when exposed to minimally elevated IOP (40 to 80 mm Hg-days).188

This increased susceptibility may reflect alterations in the responses of glia in the aged ONH to pressure-induced injury. To begin to explore this, we have examined gene expression patterns in adult and aged ONH using our rat glaucoma model.189 In general, although we found that gene expression responses to elevated IOP exposure were similar in both studies, the aged study identified only about 24% of the number genes identified in the adult study. In addition, the dynamics of the regulated responses were often altered. For example, in aged ONH, the pressure-induced increase in the mRNA for matricellular protein periostin was 47% of that in adult ONH, while the increase in that for microglial IBA1 was 220%.190

We found that aging also impacts the retinal responses to exposure to elevated IOP. In the aged retina, there is a significant augmentation the pressure-induced reduction of axonal cytoskeletal neurofilament H mRNA coupled with an attenuation of neuroprotectiveTIMP1 upregulation, as compared to the pressure-injured adult retina. 188 The relationship between aging responses and the function of specific glial cells in the retina is largely unexplored. However, in comparing gene expression in adult and aged retinas, we found that aging alone significantly upregulated the retinal mRNA for GFAP, the commonly used marker for astrocyte activation. 191

For both the retina and ONH, a clear understanding the effect of aging on the specific responses of each glial cell type in these complex tissues remains a current challenge in deciphering the mechanisms of glaucomatous neuropathy.

DISCUSSION

While recent years have dramatically increased our knowledge of the responses of glial cells in glaucomatous conditions, obviously more investigation is needed to clarify the impact of these responses on RGC and axonal survival. The upregulation of HSP in glaucomatous retinas is a case in point.138, 143, 147, 148 While the chaperone functions of HSP are generally accepted to be protective, the production of autoantibodies to HSP in human glaucoma patients raises the potential that these “neuroprotective” proteins may trigger autoimmune responses that contribute to RGC loss.177-179 It also illustrates the potential complexity of organismal, as opposed to cellular, responses.

Future investigations are needed to localize and discriminate between responses that occur simultaneously in RGC and glia. In many cases, even when a glaucomatous response is known to be glial, it has not been localized to a specific glial cell type. Because ONH astrocytes and retinal Müller cells are the most abundant glial cell types in each location, they have been more extensively studied, yet it is important to discriminate between their responses those of other glial cells. In particular, the responses of microglial cells have generally been underemphasized, despite the fact that their immune surveillance and phagocytic functions leave them beautifully equipped to participate in the glaucomatous process.

A corollary to this is the observation that endogenous glial cell responses may or may not affect adjacent RGC or axons. For example, the direct neuroprotective effects of HSP upregulation in glia are likely endogenous. In contrast, glial upregulation of neurotrophins offers the potential to enhance RGC survival in a paracrine fashion .

In addition, as pointed out in a recent review,192 glial cell contributions to the glaucomatous process may change during the course of the disease, from ones that are initially defensive and protective to those that are directed to recovery and scar formation. Our own examination of ONH in rat glaucoma illustrates the complexity of ECM gene expression changes during the course of increasing axonal involvement in the degenerative process.18

Additionally, early glial responses may not necessarily be protective. Injured glial cells may respond to glaucomatous insults in a way that enhances their own survival while simultaneously diminishing their functional support of axons or RGC. For example, early glial, presumably astrocyte, proliferation within the ONH occurs in response to elevated IOP in our rat glaucoma model, as evidenced by upregulation of cell cycle genes and dramatic increase in total ONH DNA.18 Similarly, human glaucoma is associated with an increase in immunostaining for ONH synuclein gamma, a protein associated with mitotic checkpoint regulation.193, 194 ONH astrocyte proliferation almost certainly has a negative impact on the integrity of remaining axons, because of the anatomical association of each astrocyte with multiple individual axons. Astrocyte proliferation, coupled with altered adhesion and cellular migration, implies a significant disruption of their relationships to axons. It likely diminishes the functional role of astrocytes as metabolic mediators between the axons and their vascular supply of nutrients. This may be especially important in the anterior ONH, where the metabolic demands of unmyelinated axons are likely greater.195, 196 To compound this situation, glucose utilization is increased in proliferating glia to produce ribose for nucleic acid synthesis.41 It is possible, therefore, that pressure-induced glial proliferation may result in a state of local axonal glucose deprivation in the nerve head, even in the presence of normal vascular perfusion.

In discussing glaucomatous glial responses, the relative effects of proliferation and hypertrophy have been generally ignored. In contrast to the above-discussed likelihood that astrocyte proliferation may result in passive axonal injury, glial cells undergoing hypertrophy may maintain, or even augment their specialized functions that support RGC and axons. Recently, using the DBA2j mouse glaucoma model, retinal glial responses have been characterized as non-proliferative.137 Clearly, more study is needed to clearly differentiate between glial proliferative and hypertrophic responses and their significance. In this regard, sources of proliferating cells need to be identified. In the adult retina, Müller cells have the capacity to become progenitor cells.197 In the myelinated optic nerve, oligodendroglial progenitor cells, and their role in multiple sclerosis, have also been extensively studied.198 However, it is not known if the normal ONH has a pool of progenitor cells, although a pool of presumably immature astrocytes, characterized by immunopositivity to GFAP, vimentin and nestin, has been described.199

In conclusion, the use of recently developed animal and cell culture models for glaucoma has led to the rapid expansion of our knowledge of the responses of glial cells in the ONH and retina. In many cases, these models have been verified by replicating observations originally derived from studies of human glaucoma specimens. Further refinement and application of these models offer the promise of a better understanding of glial responses to glaucomatous conditions and the potential that this knowledge will lead to enhanced therapeutic intervention in this disease.

Acknowledgments

Supported by NIH grant EY016866, EY010145 and unrestricted funds from Research to Prevent Blindness.

Footnotes

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Eye Institute or the National Institutes of Health

REFERENCES

  • 1.Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711–1720. doi: 10.1016/S0140-6736(04)16257-0. [DOI] [PubMed] [Google Scholar]
  • 2.Johnson EC, Deppmeier LM, Wentzien SK, et al. Chronology of optic nerve head and retinal responses to elevated intraocular pressure. Invest Ophthalmol Vis Sci. 2000;41:431–442. [PubMed] [Google Scholar]
  • 3.Ransom B, Behar T, Nedergaard M. New roles for astrocytes (stars at last) Trends Neurosci. 2003;26:520–522. doi: 10.1016/j.tins.2003.08.006. [DOI] [PubMed] [Google Scholar]
  • 4.Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314–1318. doi: 10.1126/science.1110647. [DOI] [PubMed] [Google Scholar]
  • 5.Hernandez MR. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res. 2000;19:297–321. doi: 10.1016/s1350-9462(99)00017-8. [DOI] [PubMed] [Google Scholar]
  • 6.Trendelenburg G, Dirnagl U. Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. Glia. 2005;50:307–320. doi: 10.1002/glia.20204. [DOI] [PubMed] [Google Scholar]
  • 7.Vesce S, Rossi D, Brambilla L, et al. Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. Int Rev Neurobiol. 2007;82:57–71. doi: 10.1016/S0074-7742(07)82003-4. [DOI] [PubMed] [Google Scholar]
  • 8.Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int. 2006;48:394–403. doi: 10.1016/j.neuint.2005.12.001. [DOI] [PubMed] [Google Scholar]
  • 9.Morrison JC. Elevated intraocular pressure and optic nerve injury models in the rat. J Glaucoma. 2005;14:315–317. doi: 10.1097/01.ijg.0000169410.09258.bf. [DOI] [PubMed] [Google Scholar]
  • 10.Morrison JC, Johnson EC, Cepurna W, et al. Understanding mechanisms of pressure-induced optic nerve damage. Prog Retin Eye Res. 2005;24:217–240. doi: 10.1016/j.preteyeres.2004.08.003. [DOI] [PubMed] [Google Scholar]
  • 11.Pang IH, Clark AF. Rodent models for glaucoma retinopathy and optic neuropathy. J Glaucoma. 2007;16:483–505. doi: 10.1097/IJG.0b013e3181405d4f. [DOI] [PubMed] [Google Scholar]
  • 12.Hernandez MR, Pena JD, Selvidge JA, et al. Hydrostatic pressure stimulates synthesis of elastin in cultured optic nerve head astrocytes. Glia. 2000;32:122–136. doi: 10.1002/1098-1136(200011)32:2<122::aid-glia20>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  • 13.Kirwan RP, Fenerty CH, Crean J, et al. Influence of cyclical mechanical strain on extracellular matrix gene expression in human lamina cribrosa cells in vitro. Mol Vis. 2005;11:798–810. [PubMed] [Google Scholar]
  • 14.Libby RT, Li Y, Savinova OV, et al. Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS genetics. 2005;1:17–26. doi: 10.1371/journal.pgen.0010004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ridet JL, Malhotra SK, Privat A, et al. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;20:570–577. doi: 10.1016/s0166-2236(97)01139-9. [DOI] [PubMed] [Google Scholar]
  • 16.Varela HJ, Hernandez MR. Astrocyte responses in human optic nerve head with primary open-angle glaucoma. J Glaucoma. 1997;6:303–313. [PubMed] [Google Scholar]
  • 17.Lam TT, Kwong JM, Tso MO. Early glial responses after acute elevated intraocular pressure in rats. Invest Ophthalmol Vis Sci. 2003;44:638–645. doi: 10.1167/iovs.02-0255. [DOI] [PubMed] [Google Scholar]
  • 18.Johnson EC, Jia L, Cepurna WO, et al. Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2007;48:3161–3177. doi: 10.1167/iovs.06-1282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Burgoyne CF, Morrison JC. The anatomy and pathophysiology of the optic nerve head in glaucoma. J Glaucoma. 2001;10:S16–18. doi: 10.1097/00061198-200110001-00007. [DOI] [PubMed] [Google Scholar]
  • 20.Downs JC, Suh JK, Thomas KA, et al. Viscoelastic material properties of the peripapillary sclera in normal and early-glaucoma monkey eyes. Invest Ophthalmol Vis Sci. 2005;46:540–546. doi: 10.1167/iovs.04-0114. [DOI] [PubMed] [Google Scholar]
  • 21.Hernandez MR, Andrzejewska WM, Neufeld AH. Changes in the extracellular matrix of the human optic nerve head in primary open-angle glaucoma. Am J Ophthalmol. 1990;109:180–188. doi: 10.1016/s0002-9394(14)75984-7. [DOI] [PubMed] [Google Scholar]
  • 22.Morrison JC, Dorman-Pease ME, Dunkelberger GR, et al. Optic nerve head extracellular matrix in primary optic atrophy and experimental glaucoma. Arch Ophthalmol. 1990;108:1020–1024. doi: 10.1001/archopht.1990.01070090122053. [DOI] [PubMed] [Google Scholar]
  • 23.Pena JD, Roy S, Hernandez MR. Tropoelastin gene expression in optic nerve heads of normal and glaucomatous subjects. Matrix Biol. 1996;15:323–330. doi: 10.1016/s0945-053x(96)90135-3. [DOI] [PubMed] [Google Scholar]
  • 24.Pena JD, Mello PA, Hernandez MR. Synthesis of elastic microfibrillar components fibrillin-1 and fibrillin-2 by human optic nerve head astrocytes in situ and in vitro. Exp Eye Res. 2000;70:589–601. doi: 10.1006/exer.1999.0817. [DOI] [PubMed] [Google Scholar]
  • 25.Urban Z, Agapova O, Hucthagowder V, et al. Population differences in elastin maturation in optic nerve head tissue and astrocytes. Invest Ophthalmol Vis Sci. 2007;48:3209–3215. doi: 10.1167/iovs.07-0107. [DOI] [PubMed] [Google Scholar]
  • 26.Pena JD, Agapova O, Gabelt BT, et al. Increased elastin expression in astrocytes of the lamina cribrosa in response to elevated intraocular pressure. Invest Ophthalmol Vis Sci. 2001;42:2303–2314. [PubMed] [Google Scholar]
  • 27.Zutter MM, Edelson BT. The alpha2beta1 integrin: a novel collectin/C1q receptor. Immunobiology. 2007;212:343–353. doi: 10.1016/j.imbio.2006.11.013. [DOI] [PubMed] [Google Scholar]
  • 28.Morrison JC. Integrins in the optic nerve head: potential roles in glaucomatous optic neuropathy (an American Ophthalmological Society thesis) Trans Am Ophthalmol Soc. 2006;104:453–477. [PMC free article] [PubMed] [Google Scholar]
  • 29.Suarez Najera I, Fernandez Ruiz B, Garcia Segura LM. Specialized contacts of astrocytes with astrocytes and with other cell types in the hypothalamus of the hamster. J Anat. 1980;130:55–61. [PMC free article] [PubMed] [Google Scholar]
  • 30.Yokosaki Y, Matsuura N, Higashiyama S, et al. Identification of the ligand binding site for the integrin alpha9 beta1 in the third fibronectin type III repeat of tenascin-C. J Biol Chem. 1998;273:11423–11428. doi: 10.1074/jbc.273.19.11423. [DOI] [PubMed] [Google Scholar]
  • 31.Gillan L, Matei D, Fishman DA, et al. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002;62:5358–5364. [PubMed] [Google Scholar]
  • 32.Schmid RS, Jo R, Shelton S, et al. Reelin, integrin and DAB1 interactions during embryonic cerebral cortical development. Cereb Cortex. 2005;15:1632–1636. doi: 10.1093/cercor/bhi041. [DOI] [PubMed] [Google Scholar]
  • 33.Conant K, St Hillaire C, Nagase H, et al. Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt. J Biol Chem. 2004;279:8056–8062. doi: 10.1074/jbc.M307051200. [DOI] [PubMed] [Google Scholar]
  • 34.Hailer NP, Bechmann I, Heizmann S, et al. Adhesion molecule expression on phagocytic microglial cells following anterograde degeneration of perforant path axons. Hippocampus. 1997;7:341–349. doi: 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  • 35.Manso AM, Elsherif L, Kang SM, et al. Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. Cardiovasc Res. 2006;69:574–584. doi: 10.1016/j.cardiores.2005.09.004. [DOI] [PubMed] [Google Scholar]
  • 36.Agapova OA, Kaufman PL, Lucarelli MJ, et al. Differential expression of matrix metalloproteinases in monkey eyes with experimental glaucoma or optic nerve transection. Brain Res. 2003;967:132–143. doi: 10.1016/s0006-8993(02)04234-8. [DOI] [PubMed] [Google Scholar]
  • 37.Agapova OA, Ricard CS, Salvador-Silva M, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia. 2001;33:205–216. doi: 10.1002/1098-1136(200103)33:3<205::aid-glia1019>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  • 38.Yan X, Tezel G, Wax MB, et al. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol. 2000;118:666–673. doi: 10.1001/archopht.118.5.666. [DOI] [PubMed] [Google Scholar]
  • 39.Ahmed Z, Dent RG, Leadbeater WE, et al. Matrix metalloproteases: degradation of the inhibitory environment of the transected optic nerve and the scar by regenerating axons. Mol Cell Neurosci. 2005;28:64–78. doi: 10.1016/j.mcn.2004.08.013. [DOI] [PubMed] [Google Scholar]
  • 40.Malone P, Miao H, Parker A, et al. Pressure induces loss of gap junction communication and redistribution of connexin 43 in astrocytes. Glia. 2007;55:1085–1098. doi: 10.1002/glia.20527. [DOI] [PubMed] [Google Scholar]
  • 41.Tabernero A, Jimenez C, Velasco A, et al. The enhancement of glucose uptake caused by the collapse of gap junction communication is due to an increase in astrocyte proliferation. J Neurochem. 2001;78:890–898. doi: 10.1046/j.1471-4159.2001.00476.x. [DOI] [PubMed] [Google Scholar]
  • 42.Mabuchi F, Aihara M, Mackey MR, et al. Optic nerve damage in experimental mouse ocular hypertension. Invest Ophthalmol Vis Sci. 2003;44:4321–4330. doi: 10.1167/iovs.03-0138. [DOI] [PubMed] [Google Scholar]
  • 43.Hernandez MR, Agapova OA, Yang P, et al. Differential gene expression in astrocytes from human normal and glaucomatous optic nerve head analyzed by cDNA microarray. Glia. 2002;38:45–64. doi: 10.1002/glia.10051. [DOI] [PubMed] [Google Scholar]
  • 44.Tezel G, Hernandez MR, Wax MB. In vitro evaluation of reactive astrocyte migration, a component of tissue remodeling in glaucomatous optic nerve head. Glia. 2001;34:178–189. doi: 10.1002/glia.1052. [DOI] [PubMed] [Google Scholar]
  • 45.Salvador-Silva M, Aoi S, Parker A, et al. Responses and signaling pathways in human optic nerve head astrocytes exposed to hydrostatic pressure in vitro. Glia. 2004;45:364–377. doi: 10.1002/glia.10342. [DOI] [PubMed] [Google Scholar]
  • 46.Furuyoshi N, Furuyoshi M, May CA, et al. Vascular and glial changes in the retrolaminar optic nerve in glaucomatous monkey eyes. Ophthalmologica. 2000;214:24–32. doi: 10.1159/000027470. [DOI] [PubMed] [Google Scholar]
  • 47.Salvador-Silva M, Ricard CS, Agapova OA, et al. Expression of small heat shock proteins and intermediate filaments in the human optic nerve head astrocytes exposed to elevated hydrostatic pressure in vitro. J Neurosci Res. 2001;66:59–73. doi: 10.1002/jnr.1197. [DOI] [PubMed] [Google Scholar]
  • 48.Schmidt JF, Agapova OA, Yang P, et al. Expression of ephrinB1 and its receptor in glaucomatous optic neuropathy. Br J Ophthalmol. 2007;91:1219–1224. doi: 10.1136/bjo.2006.112185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Du J, Tran T, Fu C, et al. Upregulation of EphB2 and ephrin-B2 at the optic nerve head of DBA/2J glaucomatous mice coincides with axon loss. Invest Ophthalmol Vis Sci. 2007;48:5567–5581. doi: 10.1167/iovs.07-0442. [DOI] [PubMed] [Google Scholar]
  • 50.Goldshmit Y, McLenachan S, Turnley A. Roles of Eph receptors and ephrins in the normal and damaged adult CNS. Brain research reviews. 2006;52:327–345. doi: 10.1016/j.brainresrev.2006.04.006. [DOI] [PubMed] [Google Scholar]
  • 51.Lambert W, Agarwal R, Howe W, et al. Neurotrophin and neurotrophin receptor expression by cells of the human lamina cribrosa. Invest Ophthalmol Vis Sci. 2001;42:2315–2323. [PubMed] [Google Scholar]
  • 52.Lambert WS, Clark AF, Wordinger RJ. Effect of exogenous neurotrophins on Trk receptor phosphorylation, cell proliferation, and neurotrophin secretion by cells isolated from the human lamina cribrosa. Mol Vis. 2004;10:289–296. [PubMed] [Google Scholar]
  • 53.Lambert WS, Clark AF, Wordinger RJ. Neurotrophin and Trk expression by cells of the human lamina cribrosa following oxygen-glucose deprivation. BMC Neurosci. 2004;5:51. doi: 10.1186/1471-2202-5-51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002;118:211–215. doi: 10.1046/j.1523-1747.2002.01641.x. [DOI] [PubMed] [Google Scholar]
  • 55.Gomes FC, Sousa Vde O, Romao L. Emerging roles for TGF-beta1 in nervous system development. Int J Dev Neurosci. 2005;23:413–424. doi: 10.1016/j.ijdevneu.2005.04.001. [DOI] [PubMed] [Google Scholar]
  • 56.Fukuchi T, Ueda J, Hanyu T, et al. Distribution and expression of transforming growth factor-beta and platelet-derived growth factor in the normal and glaucomatous monkey optic nerve heads. Jpn J Ophthalmol. 2001;45:592–599. doi: 10.1016/s0021-5155(01)00414-2. [DOI] [PubMed] [Google Scholar]
  • 57.Pena JD, Taylor AW, Ricard CS, et al. Transforming growth factor beta isoforms in human optic nerve heads. Br J Ophthalmol. 1999;83:209–218. doi: 10.1136/bjo.83.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Fuchshofer R, Birke M, Welge-Lussen U, et al. Transforming growth factor-beta 2 modulated extracellular matrix component expression in cultured human optic nerve head astrocytes. Invest Ophthalmol Vis Sci. 2005;46:568–578. doi: 10.1167/iovs.04-0649. [DOI] [PubMed] [Google Scholar]
  • 59.Lutjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp Eye Res. 2005;81:1–4. doi: 10.1016/j.exer.2005.02.008. [DOI] [PubMed] [Google Scholar]
  • 60.Wordinger RJ, Agarwal R, Talati M, et al. Expression of bone morphogenetic proteins (BMP), BMP receptors, and BMP associated proteins in human trabecular meshwork and optic nerve head cells and tissues. Mol Vis. 2002;8:241–250. [PubMed] [Google Scholar]
  • 61.Wordinger RJ, Lambert W, Agarwal R, et al. Cells of the human optic nerve head express glial cell line-derived neurotrophic factor (GDNF) and the GDNF receptor complex. Mol Vis. 2003;9:249–256. [PubMed] [Google Scholar]
  • 62.Zode GS, Clark AF, Wordinger RJ. Activation of the BMP canonical signaling pathway in human optic nerve head tissue and isolated optic nerve head astrocytes and lamina cribrosa cells. Invest Ophthalmol Vis Sci. 2007;48:5058–5067. doi: 10.1167/iovs.07-0127. [DOI] [PubMed] [Google Scholar]
  • 63.Gomes WA, Mehler MF, Kessler JA. Transgenic overexpression of BMP4 increases astroglial and decreases oligodendroglial lineage commitment. Dev Biol. 2003;255:164–177. doi: 10.1016/s0012-1606(02)00037-4. [DOI] [PubMed] [Google Scholar]
  • 64.Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000;32:42–50. [PubMed] [Google Scholar]
  • 65.Desai D, He S, Yorio T, et al. Hypoxia augments TNF-alpha-mediated endothelin-1 release and cell proliferation in human optic nerve head astrocytes. Biochem Biophys Res Commun. 2004;318:642–648. doi: 10.1016/j.bbrc.2004.04.073. [DOI] [PubMed] [Google Scholar]
  • 66.Cellini M, Possati GL, Profazio V, et al. Color Doppler imaging and plasma levels of endothelin-1 in low-tension glaucoma. Acta Ophthalmol Scand Suppl. 1997:11–13. doi: 10.1111/j.1600-0420.1997.tb00448.x. [DOI] [PubMed] [Google Scholar]
  • 67.Emre M, Orgul S, Haufschild T, et al. Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br J Ophthalmol. 2005;89:60–63. doi: 10.1136/bjo.2004.046755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sugiyama T, Moriya S, Oku H, et al. Association of endothelin-1 with normal tension glaucoma: clinical and fundamental studies. Surv Ophthalmol. 1995;39(Suppl 1):S49–56. doi: 10.1016/s0039-6257(05)80073-6. [DOI] [PubMed] [Google Scholar]
  • 69.Kaiser HJ, Flammer J, Wenk M, et al. Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. Graefes Arch Clin Exp Ophthalmol. 1995;233:484–488. doi: 10.1007/BF00183429. [DOI] [PubMed] [Google Scholar]
  • 70.Nicolela MT, Ferrier SN, Morrison CA, et al. Effects of cold-induced vasospasm in glaucoma: the role of endothelin-1. Invest Ophthalmol Vis Sci. 2003;44:2565–2572. doi: 10.1167/iovs.02-0913. [DOI] [PubMed] [Google Scholar]
  • 71.Ostrow LW, Sachs F. Mechanosensation and endothelin in astrocytes--hypothetical roles in CNS pathophysiology. Brain Res Brain Res Rev. 2005;48:488–508. doi: 10.1016/j.brainresrev.2004.09.005. [DOI] [PubMed] [Google Scholar]
  • 72.Kurihara H, Yoshizumi M, Sugiyama T, et al. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun. 1989;159:1435–1440. doi: 10.1016/0006-291x(89)92270-5. [DOI] [PubMed] [Google Scholar]
  • 73.Cioffi GA, Orgul S, Onda E, et al. An in vivo model of chronic optic nerve ischemia: the dose-dependent effects of endothelin-1 on the optic nerve microvasculature. Curr Eye Res. 1995;14:1147–1153. doi: 10.3109/02713689508995821. [DOI] [PubMed] [Google Scholar]
  • 74.Chauhan BC, LeVatte TL, Jollimore CA, et al. Model of endothelin-1-induced chronic optic neuropathy in rat. Invest Ophthalmol Vis Sci. 2004;45:144–152. doi: 10.1167/iovs.03-0687. [DOI] [PubMed] [Google Scholar]
  • 75.Oku H, Sugiyama T, Kojima S, et al. Experimental optic cup enlargement caused by endothelin-1-induced chronic optic nerve head ischemia. Surv Ophthalmol. 1999;44(Suppl 1):S74–84. doi: 10.1016/s0039-6257(99)00068-5. [DOI] [PubMed] [Google Scholar]
  • 76.Cioffi GA, Wang L, Fortune B, et al. Chronic ischemia induces regional axonal damage in experimental primate optic neuropathy. Arch Ophthalmol. 2004;122:1517–1525. doi: 10.1001/archopht.122.10.1517. [DOI] [PubMed] [Google Scholar]
  • 77.Chauhan BC, Levatte TL, Garnier KL, et al. Semiquantitative optic nerve grading scheme for determining axonal loss in experimental optic neuropathy. Invest Ophthalmol Vis Sci. 2006;47:634–640. doi: 10.1167/iovs.05-1206. [DOI] [PubMed] [Google Scholar]
  • 78.MacCumber MW, Ross CA, Snyder SH. Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc Natl Acad Sci U S A. 1990;87:2359–2363. doi: 10.1073/pnas.87.6.2359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Prasanna G, Krishnamoorthy R, Clark AF, et al. Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002;43:2704–2713. [PubMed] [Google Scholar]
  • 80.He S, Dibas A, Yorio T, et al. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells. Experimental biology and medicine (Maywood, NJ. 2007;232:370–384. [PubMed] [Google Scholar]
  • 81.He S, Prasanna G, Yorio T. Endothelin-1-mediated signaling in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in astrocytes. Invest Ophthalmol Vis Sci. 2007;48:3737–3745. doi: 10.1167/iovs.06-1138. [DOI] [PubMed] [Google Scholar]
  • 82.Prasanna G, Hulet C, Desai D, et al. Effect of elevated intraocular pressure on endothelin-1 in a rat model of glaucoma. Pharmacol Res. 2005;51:41–50. doi: 10.1016/j.phrs.2004.04.006. [DOI] [PubMed] [Google Scholar]
  • 83.Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol. 2007;47:731–759. doi: 10.1146/annurev.pharmtox.47.120505.105134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Wang L, Fortune B, Cull G, et al. Endothelin B receptor in human glaucoma and experimentally induced optic nerve damage. Arch Ophthalmol. 2006;124:717–724. doi: 10.1001/archopht.124.5.717. [DOI] [PubMed] [Google Scholar]
  • 85.Ozawa F, Kasuya Y, Hama H, et al. Microtubule dynamics regulates the level of endothelin-B receptor in rat cultured astrocytes. J Neurochem. 1997;69:562–569. doi: 10.1046/j.1471-4159.1997.69020562.x. [DOI] [PubMed] [Google Scholar]
  • 86.Malone PE, Hernandez MR. 4-Hydroxynonenal, a product of oxidative stress, leads to an antioxidant response in optic nerve head astrocytes. Exp Eye Res. 2007;84:444–454. doi: 10.1016/j.exer.2006.10.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med. 2004;10(Suppl):S18–25. doi: 10.1038/nrn1434. [DOI] [PubMed] [Google Scholar]
  • 88.Sato T, Iwaki M, Shimogaito N, et al. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med. 2006;6:351–358. doi: 10.2174/156652406776894536. [DOI] [PubMed] [Google Scholar]
  • 89.Gu L, Hagiwara S, Fan Q, et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant. 2006;21:299–313. doi: 10.1093/ndt/gfi210. [DOI] [PubMed] [Google Scholar]
  • 90.Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl. 2007:S17–26. doi: 10.1038/sj.ki.5002382. [DOI] [PubMed] [Google Scholar]
  • 91.Tezel G, Luo C, Yang X. Accelerated aging in glaucoma: immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve head. Invest Ophthalmol Vis Sci. 2007;48:1201–1211. doi: 10.1167/iovs.06-0737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115:497–503. doi: 10.1001/archopht.1997.01100150499009. [DOI] [PubMed] [Google Scholar]
  • 93.Shareef S, Sawada A, Neufeld AH. Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure. Invest Ophthalmol Vis Sci. 1999;40:2884–2891. [PubMed] [Google Scholar]
  • 94.Liu B, Neufeld AH. Expression of nitric oxide synthase-2 (NOS-2) in reactive astrocytes of the human glaucomatous optic nerve head. Glia. 2000;30:178–186. doi: 10.1002/(sici)1098-1136(200004)30:2<178::aid-glia7>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  • 95.Yuan L, Neufeld AH. Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res. 2001;64:523–532. doi: 10.1002/jnr.1104. [DOI] [PubMed] [Google Scholar]
  • 96.Liu B, Neufeld AH. Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro. Arch Ophthalmol. 2001;119:240–245. [PubMed] [Google Scholar]
  • 97.Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci U S A. 1999;96:9944–9948. doi: 10.1073/pnas.96.17.9944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Neufeld AH, Das S, Vora S, et al. A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma. J Glaucoma. 2002;11:221–225. doi: 10.1097/00061198-200206000-00010. [DOI] [PubMed] [Google Scholar]
  • 99.Vidal L, Diaz F, Villena A, et al. Nitric oxide synthase in retina and optic nerve head of rat with increased intraocular pressure and effect of timolol. Brain Res Bull. 2006;70:406–413. doi: 10.1016/j.brainresbull.2006.07.009. [DOI] [PubMed] [Google Scholar]
  • 100.Pang IH, Johnson EC, Jia L, et al. Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressure-induced optic nerve damage. Invest Ophthalmol Vis Sci. 2005;46:1313–1321. doi: 10.1167/iovs.04-0829. [DOI] [PubMed] [Google Scholar]
  • 101.Kasmala LT, Ransom NL, Conner JR, et al. Oral administration of SC-51, a nitric oxide synthase inhibitor, does not protect opotic nerve axons in a hypertensive rat model of glaucoma. Invest Ophthalmol and Visual Science. 2004 EAbstract 904. [Google Scholar]
  • 102.Libby RT, Howell GR, Pang IH, et al. Inducible nitric oxide synthase, Nos2, does not mediate optic neuropathy and retinopathy in the DBA/2J glaucoma model. BMC Neurosci. 2007;8:108. doi: 10.1186/1471-2202-8-108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Liu B, Neufeld AH. Activation of epidermal growth factor receptor signals induction of nitric oxide synthase-2 in human optic nerve head astrocytes in glaucomatous optic neuropathy. Neurobiol Dis. 2003;13:109–123. doi: 10.1016/s0969-9961(03)00010-x. [DOI] [PubMed] [Google Scholar]
  • 104.Zhang X, Neufeld AH. Activation of the epidermal growth factor receptor in optic nerve astrocytes leads to early and transient induction of cyclooxygenase-2. Invest Ophthalmol Vis Sci. 2005;46:2035–2041. doi: 10.1167/iovs.04-1473. [DOI] [PubMed] [Google Scholar]
  • 105.Zhang X, Neufeld AH. Signal transduction pathways for epidermal growth factor stimulated cyclooxygenase-2 induction in astrocytes. Exp Eye Res. 2007;85:280–288. doi: 10.1016/j.exer.2007.05.002. [DOI] [PubMed] [Google Scholar]
  • 106.Liu B, Neufeld AH. Activation of epidermal growth factor receptors directs astrocytes to organize in a network surrounding axons in the developing rat optic nerve. Dev Biol. 2004;273:297–307. doi: 10.1016/j.ydbio.2004.06.006. [DOI] [PubMed] [Google Scholar]
  • 107.Liu B, Chen H, Johns TG, et al. Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J Neurosci. 2006;26:7532–7540. doi: 10.1523/JNEUROSCI.1004-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Liu B, Neufeld AH. Activation of epidermal growth factor receptors in astrocytes: From development to neural injury. J Neurosci Res. 2007 doi: 10.1002/jnr.21364. [DOI] [PubMed] [Google Scholar]
  • 109.Wagner B, Natarajan A, Grunaug S, et al. Neuronal survival depends on EGFR signaling in cortical but not midbrain astrocytes. Embo J. 2006;25:752–762. doi: 10.1038/sj.emboj.7600988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Zelenaia O, Schlag BD, Gochenauer GE, et al. Epidermal growth factor receptor agonists increase expression of glutamate transporter GLT-1 in astrocytes through pathways dependent on phosphatidylinositol 3-kinase and transcription factor NF-kappaB. Mol Pharmacol. 2000;57:667–678. doi: 10.1124/mol.57.4.667. [DOI] [PubMed] [Google Scholar]
  • 111.Jones R, 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163–167. doi: 10.1097/01.icu.0000193079.55240.18. [DOI] [PubMed] [Google Scholar]
  • 112.Obazawa M, Mashima Y, Sanuki N, et al. Analysis of porcine optineurin and myocilin expression in trabecular meshwork cells and astrocytes from optic nerve head. Invest Ophthalmol Vis Sci. 2004;45:2652–2659. doi: 10.1167/iovs.03-0572. [DOI] [PubMed] [Google Scholar]
  • 113.Agapova OA, Yang P, Wang WH, et al. Altered expression of 3 alpha-hydroxysteroid dehydrogenases in human glaucomatous optic nerve head astrocytes. Neurobiol Dis. 2003;14:63–73. doi: 10.1016/s0969-9961(03)00101-3. [DOI] [PubMed] [Google Scholar]
  • 114.Agapova OA, Malone PE, Hernandez MR. A neuroactive steroid 5alpha-androstane-3alpha,17beta-diol regulates androgen receptor level in astrocytes. J Neurochem. 2006;98:355–363. doi: 10.1111/j.1471-4159.2006.03879.x. [DOI] [PubMed] [Google Scholar]
  • 115.Agapova OA, Kaufman PL, Hernandez MR. Androgen receptor and NFkB expression in human normal and glaucomatous optic nerve head astrocytes in vitro and in experimental glaucoma. Exp Eye Res. 2006;82:1053–1059. doi: 10.1016/j.exer.2005.10.021. [DOI] [PubMed] [Google Scholar]
  • 116.Tezel G, Yang X, Luo C, et al. Mechanisms of immune system activation in glaucoma: oxidative stress-stimulated antigen presentation by the retina and optic nerve head glia. Invest Ophthalmol Vis Sci. 2007;48:705–714. doi: 10.1167/iovs.06-0810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Yang J, Yang P, Tezel G, et al. Induction of HLA-DR expression in human lamina cribrosa astrocytes by cytokines and simulated ischemia. Invest Ophthalmol Vis Sci. 2001;42:365–371. [PubMed] [Google Scholar]
  • 118.Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752–758. doi: 10.1038/nn1472. [DOI] [PubMed] [Google Scholar]
  • 119.Garden GA, Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol. 2006;1:127–137. doi: 10.1007/s11481-006-9015-5. [DOI] [PubMed] [Google Scholar]
  • 120.Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res. 2005;81:302–313. doi: 10.1002/jnr.20562. [DOI] [PubMed] [Google Scholar]
  • 121.Liu B, Gao HM, Wang JY, et al. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci. 2002;962:318–331. doi: 10.1111/j.1749-6632.2002.tb04077.x. [DOI] [PubMed] [Google Scholar]
  • 122.Neufeld AH. Microglia in the optic nerve head and the region of parapapillary chorioretinal atrophy in glaucoma. Arch Ophthalmol. 1999;117:1050–1056. doi: 10.1001/archopht.117.8.1050. [DOI] [PubMed] [Google Scholar]
  • 123.Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci. 2006;26:12633–12641. doi: 10.1523/JNEUROSCI.2801-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Tezel G, Wax MB. The immune system and glaucoma. Curr Opin Ophthalmol. 2004;15:80–84. doi: 10.1097/00055735-200404000-00003. [DOI] [PubMed] [Google Scholar]
  • 125.Ogden TE. Nerve fiber layer astrocytes of the primate retina: morphology, distribution, and density. Invest Ophthalmol Vis Sci. 1978;17:499–510. [PubMed] [Google Scholar]
  • 126.Ramirez JM, Trivino A, Ramirez AI, et al. Structural specializations of human retinal glial cells. Vision Res. 1996;36:2029–2036. doi: 10.1016/0042-6989(95)00322-3. [DOI] [PubMed] [Google Scholar]
  • 127.Newman E, Reichenbach A. The Muller cell: a functional element of the retina. Trends Neurosci. 1996;19:307–312. doi: 10.1016/0166-2236(96)10040-0. [DOI] [PubMed] [Google Scholar]
  • 128.Tsacopoulos M, Poitry-Yamate CL, Poitry S, et al. The nutritive function of glia is regulated by signals released by neurons. Glia. 1997;21:84–91. [PubMed] [Google Scholar]
  • 129.Newman EA, Zahs KR. Modulation of neuronal activity by glial cells in the retina. J Neurosci. 1998;18:4022–4028. doi: 10.1523/JNEUROSCI.18-11-04022.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Wang X, Tay SS, Ng YK. An immunohistochemical study of neuronal and glial cell reactions in retinae of rats with experimental glaucoma. Exp Brain Res. 2000;132:476–484. doi: 10.1007/s002210000360. [DOI] [PubMed] [Google Scholar]
  • 131.Tezel G, Wax MB. Glial modulation of retinal ganglion cell death in glaucoma. J Glaucoma. 2003;12:63–68. doi: 10.1097/00061198-200302000-00014. [DOI] [PubMed] [Google Scholar]
  • 132.Steele MR, Inman DM, Calkins DJ, et al. Microarray analysis of retinal gene expression in the DBA/2J model of glaucoma. Invest Ophthalmol Vis Sci. 2006;47:977–985. doi: 10.1167/iovs.05-0865. [DOI] [PubMed] [Google Scholar]
  • 133.Tezel G, Chauhan BC, LeBlanc RP, et al. Immunohistochemical assessment of the glial mitogen-activated protein kinase activation in glaucoma. Invest Ophthalmol Vis Sci. 2003;44:3025–3033. doi: 10.1167/iovs.02-1136. [DOI] [PubMed] [Google Scholar]
  • 134.Woldemussie E, Wijono M, Ruiz G. Muller cell response to laser-induced increase in intraocular pressure in rats. Glia. 2004;47:109–119. doi: 10.1002/glia.20000. [DOI] [PubMed] [Google Scholar]
  • 135.Di Polo A, Aigner LJ, Dunn RJ, et al. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci U S A. 1998;95:3978–3983. doi: 10.1073/pnas.95.7.3978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Naskar R, Wissing M, Thanos S. Detection of early neuron degeneration and accompanying microglial responses in the retina of a rat model of glaucoma. Invest Ophthalmol Vis Sci. 2002;43:2962–2968. [PubMed] [Google Scholar]
  • 137.Inman DM, Horner PJ. Reactive nonproliferative gliosis predominates in a chronic mouse model of glaucoma. Glia. 2007;55:942–953. doi: 10.1002/glia.20516. [DOI] [PubMed] [Google Scholar]
  • 138.Ahmed F, Brown KM, Stephan DA, et al. Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure. Invest Ophthalmol Vis Sci. 2004;45:1247–1258. doi: 10.1167/iovs.03-1123. [DOI] [PubMed] [Google Scholar]
  • 139.Miyahara T, Kikuchi T, Akimoto M, et al. Gene microarray analysis of experimental glaucomatous retina from cynomologous monkey. Invest Ophthalmol Vis Sci. 2003;44:4347–4356. doi: 10.1167/iovs.02-1032. [DOI] [PubMed] [Google Scholar]
  • 140.Ju KR, Kim HS, Kim JH, et al. Retinal glial cell responses and Fas/FasL activation in rats with chronic ocular hypertension. Brain Res. 2006;1122:209–221. doi: 10.1016/j.brainres.2006.09.022. [DOI] [PubMed] [Google Scholar]
  • 141.Kuehn MH, Kim CY, Ostojic J, et al. Retinal synthesis and deposition of complement components induced by ocular hypertension. Exp Eye Res. 2006;83:620–628. doi: 10.1016/j.exer.2006.03.002. [DOI] [PubMed] [Google Scholar]
  • 142.Xue LP, Lu J, Cao Q, et al. Muller glial cells express nestin coupled with glial fibrillary acidic protein in experimentally induced glaucoma in the rat retina. Neuroscience. 2006;139:723–732. doi: 10.1016/j.neuroscience.2005.12.032. [DOI] [PubMed] [Google Scholar]
  • 143.Huang W, Fileta JB, Filippopoulos T, et al. Hsp27 phosphorylation in experimental glaucoma. Invest Ophthalmol Vis Sci. 2007;48:4129–4135. doi: 10.1167/iovs.06-0606. [DOI] [PubMed] [Google Scholar]
  • 144.Kanamori A, Nakamura M, Nakanishi Y, et al. Long-term glial reactivity in rat retinas ipsilateral and contralateral to experimental glaucoma. Exp Eye Res. 2005;81:48–56. doi: 10.1016/j.exer.2005.01.012. [DOI] [PubMed] [Google Scholar]
  • 145.Wang L, Cioffi GA, Cull G, et al. Immunohistologic evidence for retinal glial cell changes in human glaucoma. Invest Ophthalmol Vis Sci. 2002;43:1088–1094. [PubMed] [Google Scholar]
  • 146.Tezel G, Hernandez R, Wax MB. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch Ophthalmol. 2000;118:511–518. doi: 10.1001/archopht.118.4.511. [DOI] [PubMed] [Google Scholar]
  • 147.Ishii Y, Kwong JM, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003;44:1982–1992. [PubMed] [Google Scholar]
  • 148.Park KH, Cozier F, Ong OC, et al. Induction of heat shock protein 72 protects retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2001;42:1522–1530. [PubMed] [Google Scholar]
  • 149.Caprioli J, Ishii Y, Kwong JM. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Trans Am Ophthalmol Soc. 2003;101:39–50. discussion 50-31. [PMC free article] [PubMed] [Google Scholar]
  • 150.Farkas RH, Chowers I, Hackam AS, et al. Increased expression of iron-regulating genes in monkey and human glaucoma. Invest Ophthalmol Vis Sci. 2004;45:1410–1417. doi: 10.1167/iovs.03-0872. [DOI] [PubMed] [Google Scholar]
  • 151.Stasi K, Nagel D, Yang X, et al. Ceruloplasmin upregulation in retina of murine and human glaucomatous eyes. Invest Ophthalmol Vis Sci. 2007;48:727–732. doi: 10.1167/iovs.06-0497. [DOI] [PubMed] [Google Scholar]
  • 152.Klomp LW, Farhangrazi ZS, Dugan LL, et al. Ceruloplasmin gene expression in the murine central nervous system. J Clin Invest. 1996;98:207–215. doi: 10.1172/JCI118768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153.Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res. 1999;18:39–57. doi: 10.1016/s1350-9462(98)00014-7. [DOI] [PubMed] [Google Scholar]
  • 154.Martin KR, Quigley HA, Zack DJ, et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003;44:4357–4365. doi: 10.1167/iovs.02-1332. [DOI] [PubMed] [Google Scholar]
  • 155.Zhou Y, Pernet V, Hauswirth WW, et al. Activation of the extracellular signal-regulated kinase 1/2 pathway by AAV gene transfer protects retinal ganglion cells in glaucoma. Mol Ther. 2005;12:402–412. doi: 10.1016/j.ymthe.2005.04.004. [DOI] [PubMed] [Google Scholar]
  • 156.Herzog KH, von Bartheld CS. Contributions of the optic tectum and the retina as sources of brain- derived neurotrophic factor for retinal ganglion cells in the chick embryo. J Neurosci. 1998;18:2891–2906. doi: 10.1523/JNEUROSCI.18-08-02891.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157.Vecino E, Garcia-Grespo D, Garcia M, et al. Rat retinal ganglion cells co-express brain derived neurotrophic factor (BDNF) and its receptor TrkB. Vision Res. 2002;42:151–157. doi: 10.1016/s0042-6989(01)00251-6. [DOI] [PubMed] [Google Scholar]
  • 158.Yip HK, So KF. Axonal regeneration of retinal ganglion cells: effect of trophic factors. Prog Retin Eye Res. 2000;19:559–575. doi: 10.1016/s1350-9462(00)00009-4. [DOI] [PubMed] [Google Scholar]
  • 159.Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J Neurobiol. 2004;58:341–354. doi: 10.1002/neu.10293. [DOI] [PubMed] [Google Scholar]
  • 160.Taylor S, Srinivasan B, Wordinger RJ, et al. Glutamate stimulates neurotrophin expression in cultured Muller cells. Brain Res Mol Brain Res. 2003;111:189–197. doi: 10.1016/s0169-328x(03)00030-5. [DOI] [PubMed] [Google Scholar]
  • 161.Dreyer EB, Zurakowski D, Schumer RA, et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299–305. doi: 10.1001/archopht.1996.01100130295012. [DOI] [PubMed] [Google Scholar]
  • 162.Riepe RE, Norenburg MD. Muller cell localisation of glutamine synthetase in rat retina. Nature. 1977;268:654–655. doi: 10.1038/268654a0. [DOI] [PubMed] [Google Scholar]
  • 163.Rauen T. Diversity of glutamate transporter expression and function in the mammalian retina. Amino Acids. 2000;19:53–62. doi: 10.1007/s007260070033. [DOI] [PubMed] [Google Scholar]
  • 164.Carter-Dawson L, Shen F, Harwerth RS, et al. Glutamine immunoreactivity in Muller cells of monkey eyes with experimental glaucoma. Exp Eye Res. 1998;66:537–545. doi: 10.1006/exer.1997.0447. [DOI] [PubMed] [Google Scholar]
  • 165.Carter-Dawson L, Shen FF, Harwerth RS, et al. Glutathione content is altered in Muller cells of monkey eyes with experimental glaucoma. Neurosci Lett. 2004;364:7–10. doi: 10.1016/j.neulet.2004.03.082. [DOI] [PubMed] [Google Scholar]
  • 166.Harada T, Harada C, Nakamura K, et al. The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest. 2007;117:1763–1770. doi: 10.1172/JCI30178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 167.Moreno MC, Sande P, Marcos HA, et al. Effect of glaucoma on the retinal glutamate/glutamine cycle activity. Faseb J. 2005;19:1161–1162. doi: 10.1096/fj.04-3313fje. [DOI] [PubMed] [Google Scholar]
  • 168.Martin KR, Levkovitch-Verbin H, Valenta D, et al. Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat. Invest Ophthalmol Vis Sci. 2002;43:2236–2243. [PubMed] [Google Scholar]
  • 169.Wamsley S, Gabelt BT, Dahl DB, et al. Vitreous glutamate concentration and axon loss in monkeys with experimental glaucoma. Arch Ophthalmol. 2005;123:64–70. doi: 10.1001/archopht.123.1.64. [DOI] [PubMed] [Google Scholar]
  • 170.Carter-Dawson L, Crawford ML, Harwerth RS, et al. Vitreal glutamate concentration in monkeys with experimental glaucoma. Invest Ophthalmol Vis Sci. 2002;43:2633–2637. [PubMed] [Google Scholar]
  • 171.Levkovitch-Verbin H, Martin KR, Quigley HA, et al. Measurement of amino acid levels in the vitreous humor of rats after chronic intraocular pressure elevation or optic nerve transection. J Glaucoma. 2002;11:396–405. doi: 10.1097/00061198-200210000-00005. [DOI] [PubMed] [Google Scholar]
  • 172.Honkanen RA, Baruah S, Zimmerman MB, et al. Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch Ophthalmol. 2003;121:183–188. doi: 10.1001/archopht.121.2.183. [DOI] [PubMed] [Google Scholar]
  • 173.Hartwick AT, Zhang X, Chauhan BC, et al. Functional assessment of glutamate clearance mechanisms in a chronic rat glaucoma model using retinal ganglion cell calcium imaging. J Neurochem. 2005;94:794–807. doi: 10.1111/j.1471-4159.2005.03214.x. [DOI] [PubMed] [Google Scholar]
  • 174.Ullian EM, Barkis WB, Chen S, et al. Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol Cell Neurosci. 2004;26:544–557. doi: 10.1016/j.mcn.2004.05.002. [DOI] [PubMed] [Google Scholar]
  • 175.Tezel G, Yang J, Wax MB. Heat shock proteins, immunity and glaucoma. Brain Res Bull. 2004;62:473–480. doi: 10.1016/S0361-9230(03)00074-1. [DOI] [PubMed] [Google Scholar]
  • 176.Wax MB. Is there a role for the immune system in glaucomatous optic neuropathy? Curr Opin Ophthalmol. 2000;11:145–150. doi: 10.1097/00055735-200004000-00014. [DOI] [PubMed] [Google Scholar]
  • 177.Wax MB, Tezel G, Saito I, et al. Anti-Ro/SS-A positivity and heat shock protein antibodies in patients with normal-pressure glaucoma. Am J Ophthalmol. 1998;125:145–157. doi: 10.1016/s0002-9394(99)80084-1. [DOI] [PubMed] [Google Scholar]
  • 178.Wax MB, Tezel G, Kawase K, et al. Serum autoantibodies to heat shock proteins in glaucoma patients from Japan and the United States. Ophthalmology. 2001;108:296–302. doi: 10.1016/s0161-6420(00)00525-x. [DOI] [PubMed] [Google Scholar]
  • 179.Tezel G, Seigel GM, Wax MB. Autoantibodies to small heat shock proteins in glaucoma. Invest Ophthalmol Vis Sci. 1998;39:2277–2287. [PubMed] [Google Scholar]
  • 180.John SW. Mechanistic insights into glaucoma provided by experimental genetics the cogan lecture. Invest Ophthalmol Vis Sci. 2005;46:2649–2661. doi: 10.1167/iovs.05-0205. [DOI] [PubMed] [Google Scholar]
  • 181.Stasi K, Nagel D, Yang X, et al. Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes. Invest Ophthalmol Vis Sci. 2006;47:1024–1029. doi: 10.1167/iovs.05-0830. [DOI] [PubMed] [Google Scholar]
  • 182.Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164–1178. doi: 10.1016/j.cell.2007.10.036. [DOI] [PubMed] [Google Scholar]
  • 183.Weber AJ, Harman CD. Structure-function relations of parasol cells in the normal and glaucomatous primate retina. Invest Ophthalmol Vis Sci. 2005;46:3197–3207. doi: 10.1167/iovs.04-0834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184.Tezel G, Li LY, Patil RV, et al. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001;42:1787–1794. [PubMed] [Google Scholar]
  • 185.Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci. 2000;20:8693–8700. doi: 10.1523/JNEUROSCI.20-23-08693.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 186.Wang X, Ng YK, Tay SS. Factors contributing to neuronal degeneration in retinas of experimental glaucomatous rats. J Neurosci Res. 2005;82:674–689. doi: 10.1002/jnr.20679. [DOI] [PubMed] [Google Scholar]
  • 187.Bosco A, Inman DM, Steele MR, et al. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2008;49:1437–1446. doi: 10.1167/iovs.07-1337. [DOI] [PubMed] [Google Scholar]
  • 188.Cepurna WO, Jia L, Johnson EC, et al. Aging Increases Susceptibility to Intraocular Pressure (IOP) and Alters Retinal Gene Expression Responses in the Rat. Invest Ophthalmol Vis Sci. 2006;47:1243. [Google Scholar]
  • 189.Johnson EC, Doser TA, Cepurna WO, et al. Optic Nerve Head Injury in a Rat Glaucoma Model: How Does Aging Alter Gene Expression? Invest Ophthalmol Vis Sci. 2008;49:4059. [Google Scholar]
  • 190.Doser TA, Cepurna WO, Jia L, et al. Aging Alters Optic Nerve Head Gene Expression Responses to Elevated Intraocular Pressure in a Rat Glaucoma Model. Invest Ophthalmol Vis Sci. 2007;48:3277. doi: 10.1167/iovs.06-1282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 191.Johnson EC, Jia L, Cepurna WO, et al. Altered gene expression in the aged retina: Analysis by microarray and real-time RT-PCR. Invest Ophth Vis Sci. 2004;45:U789–U789. [Google Scholar]
  • 192.Nickells RW. From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can J Ophthalmol. 2007;42:278–287. [PubMed] [Google Scholar]
  • 193.Surgucheva I, McMahan B, Ahmed F, et al. Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous alterations in the optic nerve. J Neurosci Res. 2002;68:97–106. doi: 10.1002/jnr.10198. [DOI] [PubMed] [Google Scholar]
  • 194.Singh VK, Zhou Y, Marsh JA, et al. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs. Cancer Res. 2007;67:626–633. doi: 10.1158/0008-5472.CAN-06-1820. [DOI] [PubMed] [Google Scholar]
  • 195.Barron MJ, Griffiths P, Turnbull DM, et al. The distributions of mitochondria and sodium channels reflect the specific energy requirements and conduction properties of the human optic nerve head. Br J Ophthalmol. 2004;88:286–290. doi: 10.1136/bjo.2003.027664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 196.Hildebrand C, Remahl S, Persson H, et al. Myelinated nerve fibres in the CNS. Prog Neurobiol. 1993;40:319–384. doi: 10.1016/0301-0082(93)90015-k. [DOI] [PubMed] [Google Scholar]
  • 197.Reh TA, Fischer AJ. Retinal stem cells. Methods Enzymol. 2006;419:52–73. doi: 10.1016/S0076-6879(06)19003-5. [DOI] [PubMed] [Google Scholar]
  • 198.Zhao C, Zawadzka M, Roulois AJ, et al. Promoting remyelination in multiple sclerosis by endogenous adult neural stem/precursor cells: Defining cellular targets. J Neurol Sci. 2008;265:12–16. doi: 10.1016/j.jns.2007.05.008. [DOI] [PubMed] [Google Scholar]
  • 199.Yang P, Hernandez MR. Purification of astrocytes from adult human optic nerve heads by immunopanning. Brain Res Brain Res Protoc. 2003;12:67–76. doi: 10.1016/s1385-299x(03)00073-4. [DOI] [PubMed] [Google Scholar]

RESOURCES